In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals.
Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD
Learning Objectives: After completing this educational activity, you should be better able to:
- Describe the burden of residual symptoms in patients with major depressive disorder (MDD)
- Implement measurement-based care to assess residual MDD symptoms
- Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.
Credit Types: The following are being offered for this activity:
- Nurse Practitioner: ANCC contact hours
- Pharmacy: ACPE application-based contact hours
- Physician: ACCME AMA PRA Category 1 Credits ™
- Physician Associate: AAPA Category 1 CME credits
- Psychology: APA CE credits
- Social Work: ASWB-ACE CE credits
- Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™
Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented.
Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma
Interviewee
Vladimir Maletic, MD, MS
Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC
Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda
Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda
Pre-Interview Author
Caroline L. O’Brien, MS
Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.
The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.
Support: This activity is supported by an unrestricted educational grant from Takeda.
Released: November 29, 2023 CME/CE credit expires: November 29, 2026
